Schizophrenia was divided into five subtypes, including disorganized schizophrenia, paranoid schizophrenia, residual schizophrenia, undifferentiated schizophrenia, and catatonic schizophrenia per the Diagnostic and Statistical Manual of Mental Disorders (DSM IV). In 2013 the American Psychiatric Association (APA) combined all the subtypes under the general category of schizophrenia. "Catatonia" is a word that has undergone multiple definitions and loosely is associated with multiple psychomotor abnormalities and behavioral dysregulation.
Features of catatonia had been described since the 1800s with prominent physicians such as Kahlbaum and even Kraepelin, who defined catatonia within the larger definition of dementia praecox. There are several theories behind the same as catatonia can be part of a larger psychiatric or neurological illness. Kahlbaum has ultimately been credited with the understanding that symptoms such as stupor and catalepsy were part of a larger syndrome of psychomotor abnormalities, which he termed as "catatonia." This can be a part of a larger schizophrenic illness or even a bipolar affective illness or medical illness.
The advent of DSM-V has placed catatonia in its own category with schizophrenia as a specifier. Further, there are three types of catatonia that have been classified, including akinetic, hyperkinetic, and malignant catatonia.
The etiology of catatonia is multifactorial. One theory is that GABAergic (gamma-aminobutyric acid) neurotransmitters regulate both emotional and cognitive functions and disruption of the GABA pathways leads to catatonic symptoms. This theory postulates that severe negative emotions can cause "tonic immobility," leading to a lack of inhibition at the orbitofrontal cortex (OFC) and hence dysregulation between the ventromedial prefrontal cortex (VMPFC) and the dorsolateral prefrontal cortex (DLPFC), which can cause catatonic symptoms. The DLPFC helps with the cognitive understanding of negative emotions.
The epidemiology of catatonic schizophrenia can be multivariate. It is said that about 10% of patients in psychiatric inpatient services have catatonic features. On the one hand, the older school of psychiatry associated schizophrenia with catatonia, while newer epidemiological studies show that 20% of patients with catatonia have schizophrenia, and about 45% have symptoms of mood disorders and medical illness.
One prospective study showed that 7.6% of persons diagnosed with schizophrenia have catatonia. Other studies show that 10%-25% of patients with schizophrenia in the inpatient services can be classified into catatonic schizophrenia, especially when screening tools are used. This can be present at any point-first presentation schizophrenia in someone with lifelong schizophrenia with multiple prior episodes.
Dopamine has been cited as a cause of immobility and stupor, and the initial studies researched the role of dopamine in catatonia. However, these studies have been found to be inconclusive.
The N-methyl D-aspartate (NMDA) receptor has been studied extensively both clinically and in mice studies. NMDA encephalitis can produce catatonia-like symptoms. Given that, there have been reports of the use of anti-NMDA agents like amantadine in the treatment of catatonia. The neurotransmitter that is most associated with catatonia is GABA (gamma-amino-butyric acid), and it has been studied extensively. There is decreased GABAergic activity that has been detected in the left sensorimotor cortex via positron emission tomography (PET) imaging. More importantly, GABAergic drugs are the most effective in treating catatonia.
Catatonia again is a complex combination of psychomotor abnormalities and mood and thought processes. There are at least forty different signs and symptoms that have been associated with catatonia. The Diagnostic and Statistical Manual V has criteria for catatonia with specifiers, including that for schizophrenia. Three of the twelve symptoms must be present.
Walter's paper categorizes the symptoms into four major categories: 1. Motor signs (such as immobility) 2. Behavioral signs (negativism) 3. Autonomic instability (tachycardia, hyperthermia) 4. Inability to suppress motor functions (stereotypy, echolalia, echopraxia).
A complete psychiatric history, along with collateral information and a complete neurological examination is key to diagnosing catatonia in a person with schizophrenia. The onset and duration of symptom onset is key to understanding catatonia.
There is now more importance placed now on neuroimaging in cases of catatonia as there has been a noted decrease in functioning in the motor regions of the parietal and frontal cortexes of the cerebrum. Blood chemistries, blood count, serum iron, and even lumbar puncture for autoimmune antibodies for more severe cases of catatonia may be indicated.
The best way to evaluate for symptoms of catatonia is via the Bush Francis Catatonia Rating Scale (BCFRS). This is a 23 item scale, the first 14 are screening items, and two of these 14 need to be present for a positive diagnosis. The severity and description and schema are detailed. The first 14 items described as screeners include excitement, immobility/stupor, staring, posturing, grimacing, stereotypy, echopraxia/echolalia, withdrawal, mannerisms, verbigeration, rigidity, negativism, and waxy flexibility. Additional items that can be evaluated are impulsivity, automatic obedience, mitgehen, gegenhalten, ambitendency, grasp reflex, perseveration, combativeness, and autonomic abnormality.
A benzodiazepine challenge is warranted to reveal a positive diagnosis. Often 2 mg of lorazepam is given PO or IV to a patient, and remission of symptoms can be seen in 10 minutes. Studies have shown at least a 60% change in symptom presentation.
The initial management includes supportive measures such as IV fluids and even nasogastric tubes given that patients with catatonia are susceptible to malnutrition, dehydration, pneumonia, etc. The key is early identification of catatonia in a patient with schizophrenia and initiation of treatment.
If a patient is on anti-psychotic medication, this should be stopped immediately, as this may contribute to catatonia in schizophrenia.
The treatment of catatonia in schizophrenia is with benzodiazepines as the first line of treatment and then electroconvulsive therapy (ECT). The Bush-Francis group has conducted a study where they have shown a reduction in the BCFRS by 60% by administrating 2 mg of lorazepam in 10 minutes. Multiple case reports, studies, and clinical evidence now points towards the use of benzodiazepines as the standard of treatment of catatonia.
In a study of 107 people, it has been seen that two-thirds of patients studied responded adequately to the use of lorazepam. Only one-third were in remission. A large proportion of these were patients with a chronic psychotic disorder (49%), and they were trialed between 3 to 6 mg/day IV of lorazepam. The theory that benzodiazepines are partially effective in catatonic schizophrenia has been replicated on multiple clinical trials by other groups with a larger sample size as well. Most studies advocate for doses of lorazepam between 8 to 24 mg/day without causing oversedation.  Patients with catatonia can take between 3 to 7 days to respond.
ECT is to be used for patients that have failed an adequate trial of benzodiazepines. ECT is also used for rapid and malignant catatonia with autonomic dysfunction. Specifically, in catatonic schizophrenia, ECT is the treatment of choice. There have been large scale trials conducted for patients with schizophrenia with intractable catatonia. Results have shown ECT to be effective in about 100% of persons with schizophrenia; however, there is relapse within one year. The largest reviews for catatonic schizophrenia and treatment via ECT have been the chart review study conducted in Iowa. Results of the study show about 53% of persons with catatonic schizophrenia respond to ECT.
Other agents such as zolpidem have been studied for schizophrenia but not for catatonic schizophrenia. However, anti-NMDA agents like amantadine and memantine have been studied in single cases of catatonic schizophrenia and have shown some efficacy.
Lithium has also been studied but has not been studied exclusively for catatonic schizophrenia. Rather its efficacy is seen in cases of recurrent catatonia mostly associated with mood disorders.
The prognosis of catatonia is favorable if detected early and treated. It is more favorable if catatonia is associated with mood or anxiety disorders. Catatonic schizophrenia carries a poorer prognosis. Most clinical studies that have focused on the use of lorazepam in the treatment of catatonic schizophrenia show poor results. A prominent randomized double-blinded study about the use of 6 mg of lorazepam on patients with catatonic schizophrenia showed no remission in symptoms.
Another acclaimed study also studied the effects of lorazepam on patients with catatonic schizophrenia and catatonia secondary to other disorders, and importantly patients with catatonic schizophrenia showed only partial remission while the others showed full remission.
The use of ECT is encouraged in catatonia that does not respond to benzodiazepines. However, studies continue to show that catatonic schizophrenia also responds more poorly to ECT compared to catatonia secondary to mood disorders. Several theories propose that catatonic schizophrenia is "phenomenologically different" and hence does not respond as well to the use of benzodiazepines or ECT.
The group lead by Gabor S.Ungvari discusses the psychomotor symptoms that are seen in chronic schizophrenia and underdiagnosis and recognition of the same. Chronic patients may display more stereotypes, automatic mannerisms, and bizarre postures. This carries a worse prognosis in chronic schizophrenia. Gabor S.Ungvari's group has studied catatonic schizophrenia in the four main domains of motor symptoms, including negative/withdrawn phenomena, automatic phenomena, repetitive phenomena, and agitated phenomena. There are associations between sex, younger age, parkinsonism, and negative symptoms of schizophrenia with catatonia.
This group focuses upon the presence of psychomotor symptoms in both acute and chronic schizophrenia and the recognition of catatonia within this phenomenon.
Given that acute catatonia can have its origin with medical or neurological illnesses, initial monitoring with vitals signs notation and treatment with intravenous fluids and nasogastric tubes are warranted. Complications can include aspiration pneumonia, dehydration, embolisms, pressure ulcers, and malnutrition. This can be life-threatening.
The most important aspect includes early detection and treatment. When schizophrenia is traditionally discussed, the focus is usually on the positive symptoms of schizophrenia and less on the negative symptoms. Catatonic schizophrenia is a small percentage of the larger spectrum of a chronic psychotic disorder. However, given its poor prognosis, patients and families would benefit from understanding the nature of symptoms such as stereotypy, automated mannerisms, immobility, and to recognize this as an emergency.
One way of enhancing health care outcomes is by collaborating with both medical and neurological staff as catatonic schizophrenia can present as an emergency with life-threatening medical complications and autonomic instability. It is important to understand that underlying delirium or medical or neurological conditions can precipitate a catatonic state.
An interprofessional team consisting of a psychiatrist, hospitalist, nursing services, nutritional, and peer counselor would be effective in providing round the clock care to the patient with catatonic schizophrenia. Often extensive psychoeducation with an emphasis on prognosis is helpful for the family of the patient. The hospital stays are longer than regular, and patients often require months-long treatment in an inpatient service. In the outpatient setting, the benzodiazepine must be tapered off slowly to prevent relapse. It is important for both inpatient and outpatient teams to collaborate on care to prevent relapse of symptoms.
|||Ungvari GS,Gerevich J,Takács R,Gazdag G, Schizophrenia with prominent catatonic features: A selective review. Schizophrenia research. 2018 Oct; [PubMed PMID: 28818505]|
|||Fink M,Shorter E,Taylor MA, Catatonia is not schizophrenia: Kraepelin's error and the need to recognize catatonia as an independent syndrome in medical nomenclature. Schizophrenia bulletin. 2010 Mar; [PubMed PMID: 19586994]|
|||Caroff SN,Hurford I,Bleier HR,Gorton GE,Campbell EC, Recurrent Idiopathic Catatonia: Implications beyond the Diagnostic and Statistical Manual of Mental Disorders 5th Edition. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. 2015 Aug 31; [PubMed PMID: 26243853]|
|||Peralta V,Cuesta MJ,Serrano JF,Mata I, The Kahlbaum syndrome: a study of its clinical validity, nosological status, and relationship with schizophrenia and mood disorder. Comprehensive psychiatry. 1997 Jan-Feb; [PubMed PMID: 8980874]|
|||Francis A, Catatonia: diagnosis, classification, and treatment. Current psychiatry reports. 2010 Jun; [PubMed PMID: 20425278]|
|||Ellul P,Choucha W, Neurobiological Approach of Catatonia and Treatment Perspectives. Frontiers in psychiatry. 2015; [PubMed PMID: 26733892]|
|||Francis A,Fink M,Appiani F,Bertelsen A,Bolwig TG,Bräunig P,Caroff SN,Carroll BT,Cavanna AE,Cohen D,Cottencin O,Cuesta MJ,Daniels J,Dhossche D,Fricchione GL,Gazdag G,Ghaziuddin N,Healy D,Klein D,Krüger S,Lee JW,Mann SC,Mazurek M,McCall WV,McDaniel WW,Northoff G,Peralta V,Petrides G,Rosebush P,Rummans TA,Shorter E,Suzuki K,Thomas P,Vaiva G,Wachtel L, Catatonia in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. The journal of ECT. 2010 Dec; [PubMed PMID: 21099376]|
|||Rosebush PI,Mazurek MF, Catatonia and its treatment. Schizophrenia bulletin. 2010 Mar; [PubMed PMID: 19969591]|
|||Kleinhaus K,Harlap S,Perrin MC,Manor O,Weiser M,Harkavy-Friedman JM,Lichtenberg P,Malaspina D, Catatonic schizophrenia: a cohort prospective study. Schizophrenia bulletin. 2012 Mar; [PubMed PMID: 20693343]|
|||Ungvari GS,Goggins W,Leung SK,Gerevich J, Schizophrenia with prominent catatonic features ('catatonic schizophrenia'). II. Factor analysis of the catatonic syndrome. Progress in neuro-psychopharmacology [PubMed PMID: 17188791]|
|||Lauer M,Schirrmeister H,Gerhard A,Ellitok E,Beckmann H,Reske SN,Stöber G, Disturbed neural circuits in a subtype of chronic catatonic schizophrenia demonstrated by F-18-FDG-PET and F-18-DOPA-PET. Journal of neural transmission (Vienna, Austria : 1996). 2001; [PubMed PMID: 11478418]|
|||Dalmau J,Lancaster E,Martinez-Hernandez E,Rosenfeld MR,Balice-Gordon R, Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. The Lancet. Neurology. 2011 Jan; [PubMed PMID: 21163445]|
|||Sienaert P,Dhossche DM,Vancampfort D,De Hert M,Gazdag G, A clinical review of the treatment of catatonia. Frontiers in psychiatry. 2014; [PubMed PMID: 25538636]|
|||Northoff G,Steinke R,Czcervenka C,Krause R,Ulrich S,Danos P,Kropf D,Otto H,Bogerts B, Decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia: investigation of in vivo benzodiazepine receptor binding. Journal of neurology, neurosurgery, and psychiatry. 1999 Oct; [PubMed PMID: 10486389]|
|||Walther S,Strik W, Catatonia. CNS spectrums. 2016 Aug; [PubMed PMID: 27255726]|
|||Walther S,Strik W, Motor symptoms and schizophrenia. Neuropsychobiology. 2012; [PubMed PMID: 22814247]|
|||Bush G,Fink M,Petrides G,Dowling F,Francis A, Catatonia. I. Rating scale and standardized examination. Acta psychiatrica Scandinavica. 1996 Feb; [PubMed PMID: 8686483]|
|||Bush G,Fink M,Petrides G,Dowling F,Francis A, Catatonia. II. Treatment with lorazepam and electroconvulsive therapy. Acta psychiatrica Scandinavica. 1996 Feb; [PubMed PMID: 8686484]|
|||Ungvari GS,Chiu HF,Chow LY,Lau BS,Tang WK, Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study. Psychopharmacology. 1999 Mar; [PubMed PMID: 10229064]|
|||Narayanaswamy JC,Tibrewal P,Zutshi A,Srinivasaraju R,Math SB, Clinical predictors of response to treatment in catatonia. General hospital psychiatry. 2012 May-Jun; [PubMed PMID: 22387048]|
|||Beckmann H,Fritze J,Franzek E, The influence of neuroleptics on specific syndromes and symptoms in schizophrenics with unfavourable long-term course. A 5-year follow-up study of 50 chronic schizophrenics. Neuropsychobiology. 1992; [PubMed PMID: 1361971]|
|||Fink M,Taylor MA, Neuroleptic malignant syndrome is malignant catatonia, warranting treatments efficacious for catatonia. Progress in neuro-psychopharmacology [PubMed PMID: 16675086]|
|||Suzuki K,Awata S,Matsuoka H, One-year outcome after response to ECT in middle-aged and elderly patients with intractable catatonic schizophrenia. The journal of ECT. 2004 Jun; [PubMed PMID: 15167426]|
|||Morrison JR, Catatonia: prediction of outcome. Comprehensive psychiatry. 1974 Jul-Aug; [PubMed PMID: 4412345]|
|||Muneoka K,Shirayama Y,Kon K,Kawabe M,Goto M,Kimura S, Improvement of mutism in a catatonic schizophrenia case by add-on treatment with amantadine. Pharmacopsychiatry. 2010 Jun; [PubMed PMID: 20571993]|
|||Petursson H, Lithium treatment of a patient with periodic catatonia. Acta psychiatrica Scandinavica. 1976 Oct; [PubMed PMID: 998323]|
|||Lee JW,Schwartz DL,Hallmayer J, Catatonia in a psychiatric intensive care facility: incidence and response to benzodiazepines. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. 2000 Jun; [PubMed PMID: 10907800]|
|||Rohland BM,Carroll BT,Jacoby RG, ECT in the treatment of the catatonic syndrome. Journal of affective disorders. 1993 Dec; [PubMed PMID: 8126312]|
|||Ungvari GS,Caroff SN,Gerevich J, The catatonia conundrum: evidence of psychomotor phenomena as a symptom dimension in psychotic disorders. Schizophrenia bulletin. 2010 Mar; [PubMed PMID: 19776208]|
|||Ungvari GS,Leung SK,Ng FS,Cheung HK,Leung T, Schizophrenia with prominent catatonic features ('catatonic schizophrenia'): I. Demographic and clinical correlates in the chronic phase. Progress in neuro-psychopharmacology [PubMed PMID: 15610942]|
|||Clinebell K,Azzam PN,Gopalan P,Haskett R, Guidelines for preventing common medical complications of catatonia: case report and literature review. The Journal of clinical psychiatry. 2014 Jun; [PubMed PMID: 25004188]|